Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Kezar Life Sciences ( (KZR) ) is now available.
On May 11, 2026, Aurinia Pharma U.S., Inc. completed a cash-and-CVR tender offer and subsequent merger to acquire Kezar Life Sciences, Inc., paying $6.955 per share plus one contingent value right, after 80.2% of outstanding shares were validly tendered by the May 8, 2026 expiration. Following the merger, Kezar became a wholly owned subsidiary of Aurinia, its stock options were either cashed out or cancelled depending on whether they were in the money, its employee stock purchase plan was terminated, its charter and bylaws were restated, and its shares were delisted from Nasdaq with plans to terminate SEC registration and reporting obligations.
In connection with the acquisition’s completion on May 11, 2026, Kezar notified Nasdaq to suspend trading and initiate delisting, and the surviving corporation moved to end its public-company status by filing for deregistration of its shares and suspension of Exchange Act reporting. These steps mark Kezar’s transition from a publicly traded biopharmaceutical issuer to a privately held subsidiary under Aurinia’s control, reshaping governance, equity ownership, and liquidity for former shareholders and option holders.
The most recent analyst rating on (KZR) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on Kezar Life Sciences stock, see the KZR Stock Forecast page.
Spark’s Take on KZR Stock
According to Spark, TipRanks’ AI Analyst, KZR is a Neutral.
The score is held down primarily by weak financial fundamentals (ongoing losses, negative free cash flow, and equity erosion). Offsetting this are constructive technical trend signals and a positive M&A-driven catalyst, while valuation remains constrained by negative earnings and no dividend.
To see Spark’s full report on KZR stock, click here.
More about Kezar Life Sciences
Kezar Life Sciences, Inc. is a biopharmaceutical company listed on Nasdaq that focuses on developing novel therapies, with its common stock previously registered under the Securities Exchange Act and actively traded on the public markets. The company maintained equity incentive plans, including stock options and an employee stock purchase plan, to support its workforce and align employee incentives with shareholder value.
Average Trading Volume: 88,759
Technical Sentiment Signal: Hold
Current Market Cap: $53.86M
See more data about KZR stock on TipRanks’ Stock Analysis page.